CARE Series: Psychopharmacology for Substance Use Disorders Care Teams

Monday, October 7, 2024, 12:00 PM - Thursday, October 7, 2027, 1:00 PM

AMA PRA Category 1 Credits™ (1.00 hours), ANCC Nursing Contact Hours (1.00 hours), CME-Designated Participation Credit (1.00 hours)

Review of:

• Sequenced medication strategies to treat:
  • ADHD
  • Anxiety Disorders
  • Depression
  • PTSD
  • Sleep Disorders
• Considerations for patients with Substance Use Disorders
• When to refer to a psychiatrist

Presenter

Benjamin Nordstrom, MD, PhD
Chief Medical Officer
Behavioral Health Group

1. Identity first line and second line medication classes used for anxiety and depression spectrum disorders.
2. Explain considerations in psychiatric medication choices for people with Substance Use Disorders.
3. Describe a patient presentation for which referral to psychiatry would be best practice.

In support of improving patient care, Dartmouth Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

American Medical Association (AMA)
Dartmouth Health designates this Enduring Material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

American Nurses Credentialing Center (ANCC)
Dartmouth Health designates this Enduring Material for a maximum of 1.00 ANCC contact hours.

All other learners may claim CME-designated participation credit. Consult your professional licensing board regarding the applicability and acceptance of CME-designated participation credit for programs certified for credit by organizations accredited by Joint Accreditation for Interprofessional Education.

Registration/Requirements for Successful Completion
You may claim credit for successful completion of this online course. In order to claim credit, you must follow these steps:

1. Click the Register tab above. If you are not logged into your account, you will need to log in. Use the Forgot Your Password? button if you need to reset your password.
2. Register for the activity.
3. Click the Content/Tests tab and then View Content to view the recording. View the entire presentation.
4. Complete the Post-Test (attestation - return to the Content/Tests tab to find it).
5. Click the Complete Evaluation button, or click My Account in the menu bar; then click Evaluations.
6. Complete and Submit the Evaluation.

Bibliographic Sources

• Agarwal SD, Landon BE. “Patterns in outpatient benzodiazepine prescribing in the United States.” JAMA Network Open. 2019;2(1):e187399.  https://doi.org/10.1001/jamanetworkopen.2018.7399
  
  
• Breindahl T, Hindersson P. “Methylphenidate is distinguished from amphetamine in drug-of-abuse testing.” Journal of Analytical Toxicology. 36(7):538-539. 2012
  
  
• Centers for Disease Control. WONDER. https://wonder.cdc.gov/
  
  
• Cho J, Spence MM, Niu F, Hui RL, Gray P, Steinberg S. “Risk of overdose with exposure to prescription opioids, benzodiazepines and non-benzodiazepine sedative hypnotics in adults: a retrospective cohort study.” J Gen Internal Medicine. 2020. 35(3):696-703
  
  
• Evans EEA, Sullivan MA. “Abuse and misuse of antidepressants.” Substance Abuse and Rehabilitation. 5:107-120. 2014
  
  
• Eibl JK, Wilton AS, Franklyn AM, Kurdyak P, Marsh DC. “Evaluating the impact of prescribed versus non-prescribed benzodiazepine use in methadone maintenance therapy: Results from a population-based retrospective cohort study.” Journal of Addiction Medicine. 2019. 13:182-187.
  
  
• Grella CE, Karno MP, Warda US, Niv N, Moore AA. “Gender and comorbidity among individuals with opioid use disorders in the NESARC study.” Addictive Behaviors. 2009. 24(6-7): 498-504
  
  
• Lawson SG, Foudray CMA, Lowder EM, Ray B, Kory KL. “The role of co-occurring disorders in criminal recidivism and psychiatric recovery among adults with opioid use disorder and criminal-legal involvement: A statewide retrospective cohort study.” Journal of Substance Use and Addiction Treatment. 156: 2024 https://doi.org/10.1016/j.josat.2023.209192
  
  
• Leece P, Cavacuiti C, Macdonald EM, Gomes T, Kahan M, Srivasta A, Steele L, Luo J, Mamdani MM, Juurlink DN. Predictors of opioid-related death during methadone therapy.” Journal of Substance Abuse Treatment. 2015. 57: 30-35.
  
  
• Leung J, Stockings E, Wong I, Galasyuk N, Diminic S, Leitch E, Whiteford H, Degenhardt L, Ritter A, Harris M. “Co-morbid mental and substance use disorders- a meta revew of treatment effectiveness. Technical Repot Number 336. 2016 Mental Health and Alcohol and Other Drugs Branch, Queensland Health, Australia and the Australian National Health and Medical Research Council. 
  
  
• Macleod J, Steer C, Tilling K, Cornish R, Marsden J, Millar T, Strang J, Hickman M. “Prescription of benzodiazepines, z-drugs, and gabapentinoids and mortality risk in people receiving opioid agonist treatment: Clinical observational study based on the UK Clinical Practice Research Datalink and Office for National Statistics death records.” PLoS Medicine. 2019. 16:11e1002965. https://doi.org/10.1371/journal.pmed.1002965
  
  
• Malekshahi T, Tioleco N, Ahmed N, Campbell ANC, Haller D. “Misuse of atypical antipsychotics in conjunction with alcohol and other drugs of abuse.” Journal of Substance Abuse Treatment. 2015. 48(1): 8-12
  
  
• NIDA. 2021, April 13. Why is there comorbidity between substance use disorders and mental illnesses? . Retrieved from https://nida.nih.gov/publications/research-reports/common-comorbidities-substance-use-disorders/why-there-comorbidity-between-substance-use-disorders-mental-illnesses on 2024, May 30
  
  
• Nielsen S, Dietze P, Dunlop A, Taylor D. “Concurrent buprenorphine and benzodiazepine use and self-reported opioid toxicity in opioid substitution treatment.” Addiction.  2007. 102: 616-622.
  
  
• Peters RH, Young MS, Rojas EC, Gorey CM. “Evidence-based treatment and supervision practices for co-occurring mental health and substance use disorders in the criminal justice system.” American Journal of Drug and Alcohol Abuse. 43(4): 2019 https://doi.org/10.1080/00952990.2017.1303838
  
  
• Peles E, Schreiber S, Adelson M. Tricyclic antidepressant abuse, with or without benzodiazepine use, in former heroin addicts currently in methadone maintenance treatment (MMT). European Neuropsychopharmacology. 18(3):188-193. 2008
  
  
• Santos L, Rui P, Ashman JJ. “Physician office visits at which benzodiazepines were prescribed: findings from 2014-2016 National Ambulatory Medical Care Survey.” National Health Statistics Reports. 2020. 137. https://www.cdc.gov/nchs/products/index.htm.
  
  
• Smith RV, Havens JR, Walsh SL. “Gabapentin misuse, abuse, and diversion: A systematic review.” Addiction. 111(7):1160-1174. 2016
  
  
• Stein MD, Kurth ME, Sharkey KM, Anderson BJ, Corso RP, Millman RP. “Trazodone for sleep disturbance during methadone maintenance: a double blind placebo controlled trial.” Drug and Alcohol Dependence. 2012. 1:20 (1-3)
  
  
• Stein MD, Kurth ME, Anderson BJ, Blevins CE. “A pilot crossover trial of sleep medications for sleep-disturbed methadone maintenance patients.” Journal of Addiction Medicine. 2020. Published online 2019 Mar 9. https://doi.org/10.1097/ADM.0000000000000531
  
  
• Substance Abuse and Mental Health Services Administration. (2021). Key substance use and mental health indicators in the United States: Results from the 2019 National Survey on Drug Use and Health (HHS Publication No. PEP20-07-01-001, NSDUH Series H-55). Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. Retrieved from https://www.samhsa.gov/data/ 
  
  
• Tori ME, Larochelle MR, Naimi TS. “Alcohol or benzodiazepine co-involvement with opioid overdose deaths in the United States, 1999-2017. JAMA Network Open. 2020:3(4) e202361. ( https://doi.org/10.1001/jamanetworkopen.2020.2361)
  
  
• Vento AE, Kotzalidis GD, Cacciotti M, Papanti D, Orsolini L, Rapinesi C, Savoja V, Calabro G, Del Casale A, Piacentino D, Carolo M, Girardi P, Schifano F. “Quetiapine abuse fourteen years later: Where are we now? A systematic review.“Substance Use and Misuse. 55(2): 2020. 
  
  
• Wu LT, Zhu H, Swartz MS. “Treatment utilization among persons with opioid use disorder in the United States.” Drug and Alcohol Dependence. 2016. 169(1):117-127
  
  
• Xu KY, Borodovsky JT, Presnall N, Mintz CM, Hartz SM, Bierut LJ, Grucza RA. “Association between benzodiazepine or Z-drug prescreptions and drug-related poisonings among patients receiving buprenorphine maintenance: A case-crossover analysis.” AJP in Advance. ( https://doi.org/10.1176/appi.ajp.2020.20081174)
  
  

Provider Contact Information
Provider contact information for questions regarding accreditation of the activity:

Center for Learning and Professional Development
ACE Office
Dartmouth Health
[email protected]

You are not logged in.

Please click the button below to login or create a new account before continuing.

Mitigation of Relevant Financial Relationships

Dartmouth Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education.  Any individuals in a position to control the content of a CE activity, including planners, faculty, authors, or others are required to disclose all financial relationships with ineligible companies^.  All relevant financial relationships have been mitigated prior to the commencement of the activity.

^Ineligible Company is any entity whose primary business purpose is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.